Brean Capital said $PGNX MIP 1095 shows clear utility in advanced mCRPC, according to recent clinical studies. Shares are Buy rated & PT $11
According to a Nikkei Veritas survey of market pros, Toyota Motor (TM) and Hitachi (HTHIY) are the most promising Japanese stocks of 2014, Nikkei reports. Toyota is seen benefiting from the yen's depreciation and the U.S. economic recovery, while Hitachi's strong earnings are expected to continue due to its infrastructure business, Nikkei added.
Hardly a death spiral, more like a normal consolidation... the story of the tortoise and the hare applies here.
CEO Baker suffered a ski accident that incapacitated him to come to the y BIO CEOconf.
It is common practice to adjust new laws being implemented. Only in Fox newsworld and when a Dem is in the White House is it an "outrage". And this adjustment helps businesses, another point overlooked by the right wing anything Obama does is wrong types.
It's consolidating after having become very overbought... the RSI was 85... the stock is down 1.14% as I type (not bearish at all), which is not a breakdown! It's considered healthy to have a correction when a stock is overbought. It sets it up for further breakouts.
In taxane-experienced mCRPC treated with PSMA ADC at doses of 2.3 mg/kg, reductions of PSA ≥30% are seen in ~38% and reductions of ≥50% are seen in ~16% of patients • CTC conversion from unfavorable to fa vorable occurs in ~45% of patients • PSMA Expression correlates well to PSA and CTC (p=0.019) response to PSMA ADC • Low NE markers correlate well to PSA (p=0.012) response with CTC reduction of 50% in 78% of patients • 2.3 mg/kg is generally well tolerated and appears to be better tolerated than 2.5 mg/kg • A taxane-naïve cohort is ongoing
"We are encouraged by the tolerability and clear activity of PSMA ADC in this heavily pre-treated population," said Hagop Youssoufian, M.D., Executive Vice President, Research and Development. "For example, reductions in CTC's of more than 50% were seen in over 70% of patients treated."
Dr Youssoufian also said, "we look forward to the upcoming data in the less clinically advanced chemo naive setting, where our ADC technology may provide an even greater clinical benefit to men with prostate cancer."
"I've been encouraged by the response seen to date in our patients," said Daniel Petrylak, M.D., Professor of Medical Oncology at Yale Cancer Center, Clinical Research Program Leader for the Prostate and Urologic Cancers Program at Smilow Cancer Hospital at Yale-New Haven, and lead investigator on the trial. "I believe that the 2.3 mg/kg dose has been well tolerated," added Dr. Petrylak.
"We have long held the belief that PSMA expression would correlate with response, and were pleased to see that correlation in this trial. I was also pleased that another biomarker that measures low neuroendocrine disease also correlates and offers the ability to identify responders in this trial through the use of a simple blood test," said Mark R. Baker, CEO of Progenics.
ANSYS beats by $0.10, reports revs in-line; guides Q1 EPS in-line, revs in-line; guides FY14 EPS in-line, revs in-line (ANSS) : Reports Q4 (Dec) earnings of $0.96 per share, excluding non-recurring items, $0.10 better than the Capital IQ Consensus Estimate of $0.86; revenues rose 5.4% year/year to $236.7 mln vs the $237.17 mln consensus. Co issues in-line guidance for Q1, sees EPS of $0.73-0.76, excluding non-recurring items, vs. $0.76 Capital IQ Consensus Estimate; sees Q1 revs of $212-220 mln vs. $217.44 mln Capital IQ Consensus Estimate. Co issues in-line guidance for FY14, sees EPS of $3.25-3.37, excluding non-recurring items, vs. $3.32 Capital IQ Consensus Estimate; sees FY14 revs of $939-969 mln vs. $949.02 mln Capital IQ Consensus Estimate.
They would not bother to put out a press release touting a webcast if it was not positive.